Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Sectra AB's Sloan Ratio for the quarter that ended in Apr. 2026 was -7.29%.
As of Apr. 2026, Sectra AB has a Sloan Ratio of -7.29%, indicating the company is in the safe zone and there is no funny business with accruals.
Sectra AB (CHIX:SECTBs) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Apr. 2026, Sectra AB has a Sloan Ratio of -7.29%, indicating the company is in the safe zone and there is no funny business with accruals.
Sectra AB Sloan Ratio % Related Terms
Sectra AB Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Sectra AB's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:SECTBS vs ABT, SYK, MDT: Sloan Ratio % Comparison
For the Medical Devices subindustry, Sectra AB's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sectra AB Sloan Ratio % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sectra AB's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Sectra AB's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Sectra AB's Sloan Ratio for the fiscal year that ended in Apr. 2026 is calculated as
Sectra AB's Net Income for the trailing twelve months (TTM) ended in Apr. 2026 was 102.785 (Jul. 2025 ) + 148.399 (Oct. 2025 ) + 155.101 (Jan. 2026 ) + 157.493 (Apr. 2026 ) = kr564 Mil.
Sectra AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 was 118.138 (Jul. 2025 ) + 41.439 (Oct. 2025 ) + 418.09 (Jan. 2026 ) + 519.651 (Apr. 2026 ) = kr1,097 Mil.
Sectra AB's Cash Flow from Investing for the trailing twelve months (TTM) ended in Apr. 2026 was -31.228 (Jul. 2025 ) + -39.057 (Oct. 2025 ) + -64.419 (Jan. 2026 ) + -72.759 (Apr. 2026 ) = kr-207 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sectra AB (CHIX:SECTBS) has a Sloan Ratio % of -7.29% as of Apr. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Sectra AB and its competitors.
Is Sectra AB's Sloan Ratio % too high?
Sectra AB's current Sloan Ratio % is -7.29%. Overall, Sectra AB has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sectra AB's Sloan Ratio % compare to ABT and SYK?
Sectra AB's Sloan Ratio % of -7.29% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Devices & Instruments company?
A good Sloan Ratio % depends on the Medical Devices & Instruments industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Sectra AB and its competitors. Sectra AB's current Sloan Ratio % is -7.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sectra AB stock overvalued right now?
Based on GuruFocus' analysis, Sectra AB (CHIX:SECTBS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr310.49, compared to a current price of kr277.30 — trading 10.7% below its estimated fair value. The current Sloan Ratio % is -7.29%. Sectra AB's overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Sectra AB (CHIX:SECTBS), the current Sloan Ratio % is -7.29% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sectra AB (CHIX:SECTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Sectra AB stock appears to be undervalued.
The current stock price of kr277.30 is trading 10.7% below its estimated GF Value™ of kr310.49.
GuruFocus considers Sectra AB to be Modestly Undervalued.
Key valuation signals for CHIX:SECTBS:
Sloan Ratio %: -7.29%
GF Value™: kr310.49 vs. price of kr277.30 (10.7% below fair value)
No single metric tells the full story. See the CHIX:SECTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sectra AB develops IT solutions and services for storing, viewing, and working with medical images. The operating business segments are Imaging IT Solutions, Secure Communications, Business Innovation, and Other Operations. It generates maximum revenue from the Imaging IT Solutions segment. The company also offers maintenance in the form of support, system monitoring, and consulting services related to integration, system design, data migration, and business development. Geographically, it derives a majority of its revenue from the United States, followed by Sweden, the United Kingdom, the Netherlands, the Rest of Europe, and the Rest of the world.
98GF Score
Get the complete analysis for CHIX:SECTBS
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SECTBS has been successfully added to your 
